Advancements in Telix's Phase 3 ProstACT Study to be Highlighted at ASCO 2026

 Telix Pharmaceuticals is set to present preliminary safety and dosimetry findings from the initial phase of its ProstACT Global Phase 3 study at the ASCO 2026 conference. The study involves TLX591-Tx, a prostate-specific membrane antigen (PSMA)-targeted lutetium-177 radioconjugate, being administered alongside standard care for patients with PSMA-positive metastatic castration-resistant prostate cancer. The early data will focus on drug tolerability, biodistribution, and organ dose estimates, though efficacy outcomes will not yet be disclosed.

This study is notable for introducing an antibody-based radiotherapeutic in a Phase 3 clinical program comparing TLX591-Tx. Part 1 of the trial, now concluded, provided insights into dose, schedule, and safety management. The pivotal study's second part is planned to include around 490 patients who have progressed after an androgen receptor pathway inhibitor, selected through PSMA PET imaging with 68Ga-PSMA-11 agents.

Telix aims to differentiate itself in the PSMA radioligand market, which has been predominantly focused on small-molecule agents. The use of an antibody approach is expected to modify pharmacokinetics, potentially offering different safety profiles, including reduced renal and salivary gland exposure. If proven effective, this could shift the safety considerations towards more familiar hematologic or hepatic monitoring, akin to other antibody-based therapies.

Operationally, the distinction also means integrating antibody radioconjugates alongside small-molecule radionuclide therapies (RLTs). The results from the lead-in will determine whether fixed-activity dosing or individualized dosing is necessary, which will impact logistics and resources. Factors such as nuclear pharmacy capacity for handling 177Lu, as well as lab monitoring, will be critical as the study progresses.

Regulatory scrutiny will be focused on radiopharmaceutical safety, specifically organ dose constraints and long-term risks such as secondary malignancies. Collecting robust dosimetry data in Phase 3 is crucial for meeting these safety standards.

Looking ahead, the outcomes expected at ASCO 2026 will focus on rates of severe hematologic events, potential renal or salivary adverse effects, and the feasibility of outpatient dosing strategies. The success of Part 2 hinges on timely international site activation and the potential for adaptive dosing based on initial findings. Importantly, trial outcomes must align with current treatment paradigms to support broad clinical adoption, addressing both safety profiles and operational efficiency.